Eletrophilic Chemistry of Tranilast Is Involved in Its Anti-Colitic Activity via Nrf2-HO-1 Pathway Activation
Open Access
- 28 October 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (11) , 1092
Abstract
Tranilast (TRL), a synthetic derivative of a tryptophan metabolite, is an anti-allergic drug used to treat bronchial asthma. We investigated how TRL activated the nuclear factor-erythroid 2 p45-related factor 2 (Nrf2)-hemeoxygenase-1 (HO-1) pathway based on the electrophilic chemistry of the drug and whether TRL activity contributed to the treatment of rat colitis. In human colon carcinoma cells, TRL activated Nrf2, as represented by an increase in nuclear Nrf2 and induction of Nrf2-dependent luciferase and, subsequently, HO-1, a target gene product of Nrf2. TRL activation of Nrf2 and induction of HO-1 were completely prevented by chemical reduction of the electrophilic functional group (α, β-unsaturated carbonyl group) in the drug. In parallel, TRL was reactive with the nucleophilic thiol group in N-acetylcysteine, forming a covalent adduct. Moreover, TRL, but not reduced TRL, binds to Kelch-like ECH-associated protein 1 (KEAP1), releasing Nrf2. TRL administration ameliorated colonic damage and inflammation in rats with dinitrobenzene sulfonic acid-induced colitis, which was partly compromised by the chemical reduction of TRL or co-treatment with an HO-1 inhibitor. Our results suggest that TRL activated the Nrf2-HO-1 pathway via covalent binding to KEAP1, partly contributing to TRL amelioration in rat colitis.Keywords
Funding Information
- Ministry of Education (2021R1I1A3A0403710411)
This publication has 40 references indexed in Scilit:
- Mechanism of the Nrf2/Keap1/ARE signaling systemBiochemistry (Moscow), 2011
- Rectal administration of tranilast ameliorated acute colitis in mice through increased expression of heme oxygenase‐1Pathology International, 2010
- Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosisBiochemical Pharmacology, 2008
- Tranilast, an orally active anti-allergic drug, up-regulates the anti-inflammatory heme oxygenase-1 expression but down-regulates the pro-inflammatory cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW264.7 macrophagesBiochemical and Biophysical Research Communications, 2008
- The anti-allergic drug, N-(3',4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritisRheumatology, 2007
- Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn’s diseaseGut, 2007
- Nrf2-Deficient Mice Have an Increased Susceptibility to Dextran Sulfate Sodium–Induced ColitisCancer Research, 2006
- Oxidative and Electrophilic Stresses Activate Nrf2 through Inhibition of Ubiquitination Activity of Keap1Molecular and Cellular Biology, 2006
- Mechanistic Studies of the Nrf2-Keap1 Signaling PathwayDrug Metabolism Reviews, 2006
- Nrf2–Keap1 defines a physiologically important stress response mechanismTrends in Molecular Medicine, 2004